{
    "nct_id": "NCT04430855",
    "official_title": "A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa",
    "inclusion_criteria": "* Diagnosis of hidradenitis suppurativa (HS) for at least 1 year prior to Baseline.\n* Total abscess and inflammatory nodule (AN) count of ≥ 5 at Baseline, presence of HS lesions in at least 2 distinct anatomical areas, and draining fistula count of ≤ 20 at Baseline.\n* History of inadequate response or an intolerance to adequate trial of oral antibiotics for treatment of HS.\n* Required to use a daily antiseptic wash on HS lesions.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "-History of active skin disease (other than HS) that could interfere with assessment of HS, including skin infections requiring systemic treatment within 4 weeks of the Baseline visit.",
    "miscellaneous_criteria": ""
}